Health · Medical Research · 4 hrs ago
Two Experimental Approaches Show Promise Against Advanced Prostate Cancer
Researchers are testing two different experimental approaches to advanced prostate cancer, which can stop responding to treatments that reduce or block testosterone.
One approach, the daily drug bavdegalutamide, was tested in a clinical trial involving patients with advanced disease at three institutions.
About 60 percent of patients with T878/H875 mutations had a large drop in a blood marker linked to prostate cancer, compared with 3 to 4 percent of patients with other gene profiles.
The mutation group also went a median of 11 months before their cancer worsened on scans or they died, compared with about 4 to 5 months for the others.
The trial was small and had no control group, and the results do not show that the drug shrinks tumors or helps patients live longer; side effects included nausea, fatigue, vomiting and diarrhea.
A separate University of Michigan team developed DALTAC-1, which links two proteins involved in cancer growth, and tested it in cells, human-cell organoids and mice.
DALTAC-1 has not been tested in people; researchers are working to identify a candidate for human trials, while its maker is prioritizing a related drug with fewer side effects whose trial is expected to finish in May 2027.
Two experimental approaches to advanced prostate cancer are showing promise, but they involve different molecules and stages of research.
Bavdegalutamide was tested in a phase I/II clinical trial and showed stronger signs of response in patients whose tumors had T878/H875 receptor mutations.
A separate molecule, DALTAC-1, linked the androgen receptor with the helper protein p300 and showed activity against treatment-resistant tumors in preclinical studies.
DALTAC has not been tested in humans, and researchers are working to identify a candidate for clinical trials.
Bavdegalutamide caused side effects including nausea, fatigue, vomiting and diarrhea, and its developer is prioritizing a related drug with fewer side effects.
- Who
- Researchers and clinicians studied bavdegalutamide in patients; University of Michigan researchers studied DALTAC molecules in laboratory and animal models.
- What
- Bavdegalutamide showed signs of activity in some patients with advanced prostate cancer. DALTAC molecules showed preclinical activity against prostate cancer, including tumors resistant to standard treatments.
- When
- The articles were published on November 17, 2026. The DALTAC research was published in Nature; the bavdegalutamide findings were published in the Journal of Clinical Oncology.
- Where
- The bavdegalutamide trial involved Massachusetts General Hospital, Yale School of Medicine and Arvinas. The DALTAC research was conducted by researchers at the University of Michigan.
- Why
- The approaches aim to disrupt androgen-receptor signaling involved in prostate cancer growth, including in disease that resists standard treatments.
This story does not have two clearly opposing sides.
The bavdegalutamide trial’s first phase was conducted to identify a safe dosage.
The trial tested that dosage in patients with different mutations in their testosterone receptors.
- Bavdegalutamide trial sites
- Massachusetts General Hospital, Yale School of Medicine and Arvinas
- Mutation group
- T878/H875
- PSA response
- Nearly 60 percent of participants with T878/H875 mutations had PSA drops of at least half
- Median time before worsening or death
- 11 months for the T878/H875 group; about 4 to 5 months for other genetic profiles
- DALTAC research stage
- Preclinical; not tested in humans
- DALTAC potency
- Approximately 1,000 times more potent in tumor cells than separate AR and p300 inhibitors in the researchers’ comparison
2 sources
What people are saying
Our molecule acts like a molecular brace, connecting these two cancer-driving proteins in an abnormal configuration that traps them in an inactive state
The drug degrades the receptors for testosterone, which control prostate cancer growth
These are the parameters that indicate a positive response.
Our optimized molecule is approximately 1,000 times more potent in tumor cells than the combination of inhibitors targeting these proteins separately, while sparing normal cells that lack these interactions.